<DOC>
	<DOCNO>NCT02781454</DOCNO>
	<brief_summary>The purpose research study find whether drug mexiletine effective lower motor neuron electrical activity brain nerve arm people ALS . The investigator also determine sign drug may slow progression ALS reduce muscle cramp muscle twitch . This determined transcranial magnetic stimulation ( TMS ) threshold track nerve conduction study ( TTNCS ) . In trial , participant take either 300mg/day mexiletine , 600mg/day mexiletine , placebo ( non-active study drug ) .</brief_summary>
	<brief_title>Mexiletine Sporadic Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>Amyotrophic lateral sclerosis ( ALS ) neurodegenerative disorder affect primarily motor neuron , treatment design slow arrest progression remain lack . Mexiletine use-dependent sodium channel blocker FDA-approved decade treatment cardiac arrhythmia recently treat neuropathic pain diabetic polyneuropathy . Mexiletine show also protective neuron follow spinal cord , head injury , cerebral ischemia , largely block excitotoxicity . Based previous study , mexiletine appear penetrate central nervous system concentration sufficient confer significant protection . Recent unpublished study laboratory Dr. Robert Brown University Massachusetts also demonstrate mexiletine ingestion mouse genetically engineer express high level mutant cytosolic copper-zinc superoxide dismutase-1 ( SOD1 ) transgene prolongs survival animal . As mexiletine already FDA-approval anti-arrhythmic agent , much know pharmacology safety drug non-ALS patient . We anticipate exclude subject know history cardiac disease know neuroprotectant property medication , mexiletine good choice study ALS clinical trial .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Mexiletine</mesh_term>
	<criteria>1 . Sporadic ALS diagnose possible , laboratorysupported probable , probable , definite ALS define revise El Escorial criterion . 2 . Age 18 year old . 3 . Symptom onset weakness spasticity due ALS ≤ 24 month prior Screening Visit . 4 . Slow vital capacity ( SVC ) measure ≥65 % predict gender , height , age screen visit . 5 . Must able swallow capsule throughout course study , accord Site Investigator judgment . 6 . Capable provide informed consent follow trial procedure . 7 . For TMS : resting motor threshold ≤ 83 % stimulator output , 50 % pulse elicit motor evoke potential ( MEP ) amplitude ≥ 50 µV . 8 . For TTNCS : median Compound Muscle Action Potential ( CMAP ) ≥ 1.5 mV . 9 . Subjects must take riluzole least 30 day stable dose riluzole least 60 day prior Screening Visit continue stable dose throughout course study ( riluzolenaïve subject permit study ) . 10 . Subjects must take medication muscle cramp cyclobenzaprine , baclofen , carisoprodol , methocarbamol , least 30 day prior screen stable dose least 60 day prior screen . 11 . Geographic accessibility site . 12 . Women must become pregnant duration study must willing use two contraceptive therapy negative pregnancy test throughout course study . 13 . Use medication know affect neurophysiology measure study must schedule , need ( pro nata , PRN ) . A subject must fix dose 30 day prior Screening Visit , must reason believe subsequent change would necessary course study . These medication include : benzodiazepine , muscle relaxant , tricyclic antidepressant , selective serotonin reuptake inhibitor , nonselective serotonin reuptake inhibitor , hypnotic ( include antihistamine ) anticholinergic . 1 . Invasive ventilator dependence , tracheostomy . 2 . Creatinine level great 1.5 mg/dL screening . 3 . Serum GlutamicOxaloacetic ( SGOT/AST ) / Serum GlutamicPyruvic ( SGPT/ALT ) great 3 time upper limit normal screening . 4 . History known sensitivity intolerability mexiletine lidocaine . 5 . Any history either substance abuse within past year , unstable psychiatric disease , cognitive impairment , dementia . 6 . Clinically significant conduction abnormality electrocardiogram know history cardiac arrhythmia . 7 . Known history epilepsy . 8 . Known history congestive heart failure ( CHF ) history myocardial infarction within past 24 month . 9 . Use mexiletine 60 day prior Screening Visit . 10 . Exposure experimental agent ( offlabel use investigational ) include high dose creatine ( &gt; 10 gram day ) within 30 day prior Screening Visit . 11 . Metal head neck region , cardiac pacemaker brain stimulator , cochlear implant , implant infusion device personal history epilepsy . 12 . Use amiodarone , flecainide , duloxetine , tizanidine , clozapine . 13 . Pregnant woman woman currently breastfeed . 14 . Placement Diaphragm Pacing System ( DPS ) device &lt; 60 day prior Screening Visit . 15 . Planned DPS device implantation study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>SALS</keyword>
	<keyword>Mexiletine</keyword>
	<keyword>TMS</keyword>
	<keyword>NCS</keyword>
</DOC>